Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.
Saved in:
| Title: | Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. |
|---|---|
| Authors: | Andersen R; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Jespersen MS; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Presti M; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Bjornhart B; Department of Oncology, Odense University Hospital, Odense, Denmark., Østby AC; Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Darras AKM; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Garitaonaindia Y; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Ruhlmann CH; Department of Oncology, Odense University Hospital, Odense, Denmark., Frank MS; Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Schmidt H; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Friis RB; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Guldbrandt LM; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Henriksen JR; Department of Oncology, Odense University Hospital, Odense, Denmark., Bjerrum A; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Simonsen KS; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Palshof JA; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Borch TH; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Andersen JL; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Kjaer S; Department of Oncology, Odense University Hospital, Odense, Denmark., Jensen NV; Department of Oncology, Odense University Hospital, Odense, Denmark., Azimi A; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Iversen AB; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Steen SG; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Khan S; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Luczak AA; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark., Wahlstrøm S; Department of Oncology, North Zealand Hospital, Hilleroed, Denmark., Zitnjak D; Department of Oncology, South Jutland Hospital, Soenderborg, Denmark., Svane IM; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Fristrup N; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Kristiansen C; Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Persson GF; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Bastholt L; Department of Oncology, Odense University Hospital, Odense, Denmark., Poehl M; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Ellebaek E; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Donia M; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: marco.donia@regionh.dk. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jun 05; Vol. 243, pp. 116872. Date of Electronic Publication: 2026 Jun 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
